Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status

Medicina (Kaunas). 2021 Nov 19;57(11):1273. doi: 10.3390/medicina57111273.ABSTRACTImmune checkpoint inhibitors (ICIs) are standard treatments for patients with lung cancer. PD-1/PD-L1 or CTLA4 antibodies are chosen as the first-line therapy, contributing to the long-term survival and tolerability. Unlike molecular targeting agents, such as gefitinib, lung cancer patients with a poor performance status (PS) display unsatisfactory clinical improvements after ICI treatment. Several previous reports also demonstrated that the PS is identified as one of the most probable prognostic factors for predicting poor outcomes after ICI treatment. However, first-line pembrolizumab seemed to be effective for lung cancer patients with a PS of 2 if PD-L1 expression was greater than 50%. Currently, the induction of ICIs in patients with lung cancer with a poor PS is controversial. These problems are discussed in this review.PMID:34833490 | PMC:PMC8618581 | DOI:10.3390/medicina57111273

Source: Medicina (Kaunas) - November 27, 2021 Category: Universities & Medical Training Authors: Kyoichi Kaira Hisao Imai Atsuto Mouri Ou Yamaguchi Hiroshi Kagamu Source Type: research